JPH09501680A - Ｈ▲下２▼−アンタゴニストの経口組成物 - Google Patents

Ｈ▲下２▼−アンタゴニストの経口組成物

Info

Publication number: JPH09501680A
Authority: JP; Japan
Prior art keywords: composition; composition according; calcium carbonate; antagonist; magnesium aluminum
Prior art date: 1993-08-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP7507128A

Other languages

English (en)

Japanese (ja)

Inventor

ヘンリーシー．カルドウェル

アスボックジェイ．デサイ

Original Assignee

アプライドアナリティカルインダストリーズ，インク．

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-17

Filing date

1994-08-16

Publication date

1997-02-18

1994-08-16 Application filed by アプライドアナリティカルインダストリーズ，インク． filed Critical アプライドアナリティカルインダストリーズ，インク．

1997-02-18 Publication of JPH09501680A publication Critical patent/JPH09501680A/ja

Status Pending legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 50
239000005557 antagonist Substances 0.000 title claims description 17
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 41
229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 20
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims abstract description 16
239000004480 active ingredient Substances 0.000 claims abstract description 15
239000007910 chewable tablet Substances 0.000 claims abstract description 15
238000009472 formulation Methods 0.000 claims abstract description 15
239000003485 histamine H2 receptor antagonist Substances 0.000 claims abstract description 12
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 6
229940068682 chewable tablet Drugs 0.000 claims abstract description 6
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 6
239000000811 xylitol Substances 0.000 claims abstract description 6
235000010447 xylitol Nutrition 0.000 claims abstract description 6
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 6
229960002675 xylitol Drugs 0.000 claims abstract description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
239000003814 drug Substances 0.000 claims description 16
229940079593 drug Drugs 0.000 claims description 14
229960004872 nizatidine Drugs 0.000 claims description 6
SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 claims description 6
229960000620 ranitidine Drugs 0.000 claims description 6
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 6
231100000252 nontoxic Toxicity 0.000 claims description 5
230000003000 nontoxic effect Effects 0.000 claims description 5
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
229930195725 Mannitol Natural products 0.000 claims description 4
229960001380 cimetidine Drugs 0.000 claims description 4
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 4
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 4
229960001596 famotidine Drugs 0.000 claims description 4
239000000594 mannitol Substances 0.000 claims description 4
235000010355 mannitol Nutrition 0.000 claims description 4
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
235000015165 citric acid Nutrition 0.000 claims description 3
239000001630 malic acid Substances 0.000 claims description 3
235000011090 malic acid Nutrition 0.000 claims description 3
239000003765 sweetening agent Substances 0.000 claims description 3
239000011975 tartaric acid Substances 0.000 claims description 3
235000002906 tartaric acid Nutrition 0.000 claims description 3
239000002253 acid Substances 0.000 abstract description 12
239000004615 ingredient Substances 0.000 abstract description 5
150000007513 acids Chemical class 0.000 abstract description 4
235000013399 edible fruits Nutrition 0.000 abstract description 4
230000009967 tasteless effect Effects 0.000 abstract description 2
239000002671 adjuvant Substances 0.000 abstract 1
239000008187 granular material Substances 0.000 description 15
238000000034 method Methods 0.000 description 10
239000003826 tablet Substances 0.000 description 7
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 5
150000001875 compounds Chemical class 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 3
239000003463 adsorbent Substances 0.000 description 3
235000019658 bitter taste Nutrition 0.000 description 3
239000001569 carbon dioxide Substances 0.000 description 3
229910002092 carbon dioxide Inorganic materials 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
-1 halide salts Chemical class 0.000 description 3
239000007937 lozenge Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
GIMNAEMRNXUAQP-UHFFFAOYSA-N 2-[4-(2-methyl-1h-imidazol-5-yl)-1,3-thiazol-2-yl]guanidine Chemical compound N1C(C)=NC=C1C1=CSC(N=C(N)N)=N1 GIMNAEMRNXUAQP-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
239000013065 commercial product Substances 0.000 description 2
GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
VTLNPNNUIJHJQB-UHFFFAOYSA-N loxtidine Chemical compound CN1N=C(CO)N=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 VTLNPNNUIJHJQB-UHFFFAOYSA-N 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229960001855 mannitol Drugs 0.000 description 2
229950008866 mifentidine Drugs 0.000 description 2
229910052901 montmorillonite Inorganic materials 0.000 description 2
GOZUADYOHPCXLE-UHFFFAOYSA-N n-[4-(1h-imidazol-5-yl)phenyl]-n'-propan-2-ylmethanimidamide Chemical compound C1=CC(NC=NC(C)C)=CC=C1C1=CN=CN1 GOZUADYOHPCXLE-UHFFFAOYSA-N 0.000 description 2
235000019629 palatability Nutrition 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
150000004760 silicates Chemical class 0.000 description 2
239000000126 substance Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
229950003675 zaltidine Drugs 0.000 description 2
YDDXVAXDYKBWDX-UHFFFAOYSA-N 1-cyano-3-[2-[[2-(diaminomethylideneamino)-4-thiazolyl]methylthio]ethyl]-2-methylguanidine Chemical compound N#CNC(=NC)NCCSCC1=CSC(N=C(N)N)=N1 YDDXVAXDYKBWDX-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010013911 Dysgeusia Diseases 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
NRIGRKAXOLMTSK-UHFFFAOYSA-N Lamtidine Chemical compound CN1N=C(N)N=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 NRIGRKAXOLMTSK-UHFFFAOYSA-N 0.000 description 1
SMTZFNFIKUPEJC-UHFFFAOYSA-N Roxane Chemical compound CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 SMTZFNFIKUPEJC-UHFFFAOYSA-N 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
239000002535 acidifier Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002156 adsorbate Substances 0.000 description 1
229940069428 antacid Drugs 0.000 description 1
239000003159 antacid agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001458 anti-acid effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000003699 antiulcer agent Substances 0.000 description 1
229960000892 attapulgite Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000004927 clay Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
235000019820 disodium diphosphate Nutrition 0.000 description 1
GYQBBRRVRKFJRG-UHFFFAOYSA-L disodium pyrophosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 description 1
238000011978 dissolution method Methods 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
238000005187 foaming Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
239000003453 histamine agonist Substances 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229950003849 lamtidine Drugs 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229910052625 palygorskite Inorganic materials 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
229960001520 ranitidine hydrochloride Drugs 0.000 description 1
GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
238000010992 reflux Methods 0.000 description 1
229960003320 roxatidine Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011973 solid acid Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
235000019640 taste Nutrition 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229950011533 tiotidine Drugs 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Inorganic Chemistry (AREA)
Zoology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP7507128A 1993-08-17 1994-08-16 Ｈ▲下２▼−アンタゴニストの経口組成物 Pending JPH09501680A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US10712693A	1993-08-17	1993-08-17
US08/107,126		1993-08-17
US28871194A	1994-08-12	1994-08-12
US08/288,711		1994-08-12
PCT/US1994/009204 WO1995005173A1 (en)	1993-08-17	1994-08-16	Oral compositions of h2-antagonists

Publications (1)

Publication Number	Publication Date
JPH09501680A true JPH09501680A (ja)	1997-02-18

Family

ID=26804421

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP7507128A Pending JPH09501680A (ja)	1993-08-17	1994-08-16	Ｈ▲下２▼−アンタゴニストの経口組成物

Country Status (5)

Country	Link
EP (1)	EP0715516A1 (de)
JP (1)	JPH09501680A (de)
AU (1)	AU7565594A (de)
CA (1)	CA2169735A1 (de)
WO (1)	WO1995005173A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5622980A (en) *	1993-08-17	1997-04-22	Applied Analytical Industries, Inc.	Oral compositions of H2-antagonists
US6537525B1 (en) *	1997-01-29	2003-03-25	Douglas H. West	Medicated chewing-gum
DE10200405A1 (de)	2002-01-08	2002-08-01	Zimmer Ag	Spinnvorrichtung und -verfahren mit Kühlbeblasung
DE10204381A1 (de)	2002-01-28	2003-08-07	Zimmer Ag	Ergonomische Spinnanlage
DE10206089A1 (de)	2002-02-13	2002-08-14	Zimmer Ag	Bersteinsatz
US20100226979A1 (en) *	2006-03-21	2010-09-09	Jubilant Organosys Limited	Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate
EP3706619B1 (de)	2017-11-09	2024-04-24	ConvaTec Technologies Inc.	Vorrichtung zur überwachung eines stomas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100238565B1 (ko) *	1991-04-04	2000-02-01	데이비드 엠 모이어	상부 위장관 통증을 치료하기 위한 섭취가능한 약학적 조성물
US5229137A (en) *	1992-05-06	1993-07-20	Brigham And Women's Hospital, Inc.	Methods and pharmaceutical compositions for treating episodic heartburn

1994
- 1994-08-16 WO PCT/US1994/009204 patent/WO1995005173A1/en not_active Ceased
- 1994-08-16 CA CA 2169735 patent/CA2169735A1/en not_active Abandoned
- 1994-08-16 JP JP7507128A patent/JPH09501680A/ja active Pending
- 1994-08-16 AU AU75655/94A patent/AU7565594A/en not_active Abandoned
- 1994-08-16 EP EP94925883A patent/EP0715516A1/de not_active Withdrawn

Also Published As

Publication number	Publication date
WO1995005173A1 (en)	1995-02-23
AU7565594A (en)	1995-03-14
EP0715516A1 (de)	1996-06-12
CA2169735A1 (en)	1995-02-23

Publication	Publication Date	Title
AU681672B2 (en)	1997-09-04	Preparations containing silicon dioxide to improve the taste thereof
JP4445590B2 (ja)	2010-04-07	パロキセチン−レジン含有の経口液体組成物
JP2918691B2 (ja)	1999-07-12	ラニチジン組成物
US20030083354A1 (en)	2003-05-01	Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
AU703242B2 (en)	1999-03-25	Film coated tablet of paracetamol and domperidone
HU211592A9 (en)	1995-12-28	Ranitidine resin adsorbates
EP0349103B1 (de)	1992-11-25	Kautablette
JP3038456B2 (ja)	2000-05-08	ジデオキシプリンヌクレオシドの改良された経口投与処方物
EA017832B1 (ru)	2013-03-29	Гранулы и орально дезинтегрируемые таблетки, содержащие оксикодон
JPH05112445A (ja)	1993-05-07	作用開始を速くし潜在特性を増加させる移送システム
JP3518601B2 (ja)	2004-04-12	エバスタイムまたはその類似体に基づく医薬組成物
US5468504A (en)	1995-11-21	Effervescent pharmaceutical compositions
US5622980A (en)	1997-04-22	Oral compositions of H2-antagonists
JP2001513801A (ja)	2001-09-04	パラセタモールを含む嚥下錠剤
JPH09501680A (ja)	1997-02-18	Ｈ▲下２▼−アンタゴニストの経口組成物
US20090269393A1 (en)	2009-10-29	Chewable Bilayer Tablet Formulation
JP2001097856A (ja)	2001-04-10	鎮咳剤
CN1739513A (zh)	2006-03-01	一种氯雷他定口腔崩解片剂及其制备方法
JP2005516943A (ja)	2005-06-09	経口投与に適した医薬品懸濁液
US20040132827A1 (en)	2004-07-08	Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions
CA2099585C (en)	2003-09-30	Pharmaceutical compositions
JPH07165590A (ja)	1995-06-27	医薬組成物
WO1996004888A1 (en)	1996-02-22	Oral compositions of h2-antagonists
CN1830442A (zh)	2006-09-13	复方右美沙芬口腔崩解片及其制备方法
JPS63310829A (ja)	1988-12-19	ジフルニサ−ル及びトロメタミンの混合剤